Analyst Ratings For Heron Therapeutics (NASDAQ:HRTX)
Today, Needham & Company LLC raised its price target on Heron Therapeutics (NASDAQ:HRTX) to $30.00 per share.
Some recent analyst ratings include
- 1/16/2018-Mizuho Reiterated Rating of Buy.
- 1/2/2018-Leerink Swann initiated coverage with a Outperform rating.
- 12/6/2017-Cowen Reiterated Rating of Buy.
- On 1/10/2018 Kimberly Manhard, VP, sold 7,584 with an average share price of $20.00 per share and the total transaction amounting to $151,680.00.
- On 4/24/2017 Kimberly Manhard, VP, sold 21,542 with an average share price of $15.33 per share and the total transaction amounting to $330,238.86.
- On 1/19/2017 Kevin C Tang, Director, bought 2,459,016 with an average share price of $12.20 per share and the total transaction amounting to $29,999,995.20.
- On 8/10/2016 Robert Rosen, Insider, sold 100,000 with an average share price of $23.30 per share and the total transaction amounting to $2,330,000.00.
- On 4/21/2016 Robert Rosen, President, sold 200,000 with an average share price of $23.23 per share and the total transaction amounting to $4,646,000.00.
- On 6/10/2015 Kevin C Tang, Director, bought 121,212 with an average share price of $24.75 per share and the total transaction amounting to $2,999,997.00.
- On 6/2/2015 Kevin C Tang, Director, bought 150,000 with an average share price of $20.62 per share and the total transaction amounting to $3,093,000.00.
Recent Trading Activity for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics closed the previous trading session at 20.25 down -0.10 0.49% with 20.149999618530273 shares trading hands.